Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 12:00PM GMT
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang, I'm [a biotech] analyst from Barclays.

It is my great pleasure to introduce our first speaker, Tom Kassberg, Chief Business Officer of Ultragenyx.

Thomas R. Kassberg
Ultragenyx Pharmaceutical Inc. - Chief Business Officer & Executive VP

Thanks, Gena. Let me see -- figure out the slides. So I'm Tom Kassberg, Chief Business Officer of Ultragenyx, and I'm pleased to be here to talk to you about Ultragenyx today.

So standard legal warning for the presentation to follow. So Ultragenyx, for some of you, I'll give you a quick introduction, was founded in 2010, went IPO in 2014. And it's an -- we talk about as a company that was built rare by design. So from the beginning, developed as a specialist rare disease company. We have -- in terms of -- we forged many new approaches and with multiple modalities that we currently employ to address these rare diseases. About 1.5 years ago, we added a gene therapy platform, which is now an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot